Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Incyte reported positive pivotal Phase 3 frontMIND trial results for tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP in previously untreated high-risk DLBCL and HGBL. The combination significantly prolonged progression-free survival, reducing the risk of disease progression or death by 25% (HR 0.75, p=0.0194) compared to R-CHOP alone, with benefits observed across key molecular subgroups.
Key figures
- Drug Name
- Tafasitamab (Monjuvi/Minjuvi)
- Phase Of Trial
- Phase 3
- Os hazard ratio
- 0.85
- Pfs 2yr control
- 62.9%
- Pfs 3yr control
- 60.7%
- Efs hazard ratio
- 0.79
- Enrollment count
- 899
- Pfs hazard ratio
- 0.75
- Pfs 2yr treatment
- 71.1%
- Pfs 3yr treatment
- 67.3%
- Pfs risk reduction
- 25%
- Mrd negativity control
- 66.7%
- Median follow up months
- 35.2
- Mrd negativity treatment
- 81.3%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.